Congenital Adrenal Hyperplasia Market Report 2026

The congenital adrenal hyperplasia market size has grown strongly in recent years. It will grow from $0.5 billion in 2025 to $0.53 billion in 2026 at a compound annual growth rate (CAGR) of 7.1%. The growth in the historic period can be attributed to limited enzyme replacement options, reliance on lifelong glucocorticoid therapy, low awareness in developing regions, delayed diagnosis due to lack of screening, dependence on hospital-based endocrinology care.

The congenital adrenal hyperplasia market size is expected to see strong growth in the next few years. It will grow to $0.7 billion in 2030 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to advancements in precision medicine approaches, expansion of genetic testing access, increasing healthcare expenditure, growth in specialty clinics, improved patient adherence through novel formulations. Major trends in the forecast period include expanded newborn screening programs, long-acting and modified-release steroid therapies, improved mineralocorticoid and androgen suppression regimens, rising adoption of multidisciplinary care models, increasing focus on lifelong disease management.

The growing demand for gene therapy is anticipated to drive the expansion of the congenital adrenal hyperplasia market in the coming years. Gene therapy is a medical approach that involves altering or manipulating an individual’s genes to treat or prevent diseases. The increasing demand for gene therapy is driven by advances in genetic research and biotechnology, which have enabled more accurate and targeted treatment options for genetic disorders, cancer, and other chronic conditions. Congenital adrenal hyperplasia (CAH), which arises from mutations in genes responsible for adrenal hormone production, represents an important focus area for gene therapy, as it offers opportunities for targeted genetic interventions to correct underlying defects and restore normal hormone function. For example, in April 2024, according to the American Society of Gene and Cell Therapy (ASGCT), a US-based professional membership organization, of the 1,023 gene therapies under development for rare diseases, eight of the top ten rare diseases were related to oncology. In the second quarter of 2024, 76 gene therapy trials were initiated, reflecting a 25% increase compared with the previous quarter. Consequently, the rising demand for gene therapy is supporting the growth of the congenital adrenal hyperplasia market.

Key companies operating in the congenital adrenal hyperplasia market are emphasizing the development of innovative treatment options such as CRF1 receptor antagonists to help regulate cortisol production and reduce excess adrenal androgen levels. A CRF1 receptor antagonist is a drug that blocks the corticotropin-releasing factor 1 (CRF1) receptor, thereby modulating the body’s stress response and lowering excessive adrenal androgen production in conditions like congenital adrenal hyperplasia. For instance, in December 2024, Neurocrine Biosciences, Inc., a US-based biopharmaceutical company, received FDA approval for Crenessity (crinecerfont), the first new treatment for congenital adrenal hyperplasia in 70 years. This oral therapy functions as a selective corticotropin-releasing factor type 1 receptor antagonist, helping to control elevated adrenocorticotropic hormone (ACTH) and adrenal androgen levels while allowing reduced glucocorticoid dosing. The approval was supported by results from the CAHtalyst Phase 3 studies, which demonstrated significant effectiveness in lowering androgen levels. Crenessity is expected to become available in the near term, representing a notable advancement in CAH treatment.

In January 2023, Spruce Biosciences Inc., a US-based biotechnology company, entered into a partnership with Kaken Pharmaceutical Co., Ltd. to develop and commercialize tildacerfont for congenital adrenal hyperplasia (CAH) in Japan. Through this collaboration, Spruce Biosciences and Kaken seek to accelerate clinical development and regional commercialization by combining Spruce’s tildacerfont clinical program and regulatory data with Kaken’s development, regulatory, and commercial capabilities in the Japanese market, with the aim of improving patient access to a potential non-steroidal therapy for CAH. Kaken Pharmaceutical Co., Ltd. is a Japan-based pharmaceutical company focused on the development, manufacturing, and commercialization of prescription medicines.

Major companies operating in the congenital adrenal hyperplasia market are Pfizer Inc., Sanofi S.A., Thermo Fisher Scientific Inc., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Eton Pharmaceuticals Inc, Teva Pharmaceutical Industries, Macleods Pharmaceuticals, H. Lundbeck A/S, Neurocrine Biosciences Inc., BridgeBio Pharma Inc, Regenxbio Inc., Millendo Therapeutics Inc., Applied Therapeutics, Inc., OMass Therapeutics Limited, ViennaLab Diagnostics GmbH, EffRx Pharmaceuticals SA, Adrenas Therapeutics Inc, HBM Alpha Therapeutics, Spruce Biosciences Inc., Crinetics Pharmaceuticals Inc.

North America was the largest region in the congenital adrenal hyperplasia market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the congenital adrenal hyperplasia market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the congenital adrenal hyperplasia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the congenital adrenal hyperplasia market by increasing costs of imported pharmaceutical ingredients, diagnostic reagents, genetic testing equipment, and hormone formulations. Specialty clinics and hospitals in North America and Europe are most affected due to reliance on imported active pharmaceutical ingredients, while Asia-Pacific faces higher costs in diagnostic infrastructure. These tariffs are increasing treatment and testing expenses. However, they are also encouraging domestic drug manufacturing, regional diagnostic capability development, and improved supply chain resilience for rare disease therapies.

The congenital adrenal hyperplasia market research report is one of a series of new reports that provides congenital adrenal hyperplasia market statistics, including congenital adrenal hyperplasia industry global market size, regional shares, competitors with a congenital adrenal hyperplasia market share, detailed congenital adrenal hyperplasia market segments, market trends and opportunities, and any further data you may need to thrive in the congenital adrenal hyperplasia industry. This congenital adrenal hyperplasia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Congenital adrenal hyperplasia is a group of inherited conditions that impair adrenal gland function due to enzyme deficiencies, most commonly 21-hydroxylase. The condition is treated using hormone replacement therapy to restore cortisol and aldosterone levels, reduce excessive androgen production, and manage related symptoms such as electrolyte imbalances and abnormal physical development.

The primary forms of congenital adrenal hyperplasia (CAH) include classic congenital adrenal hyperplasia and non-classic congenital adrenal hyperplasia. Classic CAH is a genetic condition mainly caused by 21-hydroxylase deficiency, resulting in cortisol deficiency, elevated androgen levels, and potential aldosterone loss. Diagnosis and management are carried out across multiple healthcare settings, including hospitals, specialty clinics, ambulatory surgical centers, and research institutes.

The congenital adrenal hyperplasia market consists of revenues earned by entities by providing services such as telemedicine and remote monitoring, diagnostic testing services, hormone replacement therapy (HRT) services, and surgical interventions. The market value includes the value of related goods sold by the service provider or included within the service offering. The congenital adrenal hyperplasia market also includes sales of glucocorticoids, mineralocorticoids, and adrenal androgens. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.